Mendelian randomization (MR) has unravelled many new insights into the causal mechanisms driving disease.^1,2 Whilst elucidation of the aetiological role of risk factors and biomarkers in disease [e.g. blood lipids in coronary artery disease (CAD)³] is of clinical and public health importance, it is also valuable to know whether particular pharmacological targets, typically proteins, are of therapeutic relevance in specific diseases.

中文翻译：

---

利用人类遗传学来指导药物的重新利用。

孟德尔随机化 (MR) 揭示了许多关于疾病因果机制的新见解。^{1 , 2}虽然阐明疾病中危险因素和生物标志物的病因学作用 [例如冠状动脉疾病 (CAD) ³中的血脂] 具有临床和公共卫生重要性，但了解特定的药理学目标（通常是蛋白质）是否也很有价值，对特定疾病具有治疗相关性。